Marketing insulinsBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d471 (Published 25 January 2011) Cite this as: BMJ 2011;342:d471
- Robert Tattersall, retired professor of clinical diabetes1
- 1Sheffield S11 7EJ, UK
Cohen and Carter point out the lack of evidence that analogues are better than human insulin and conclude that marketing accounts for their success.1 We have been here before.
In the 1970s, human insulin was thought in some unspecified way to be better than animal insulin, and Novo and Eli Lilly started a race to make and …